145 related articles for article (PubMed ID: 30227876)
1. Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates.
Bagaglio S; Uberti-Foppa C; Olgiati A; Messina E; Hasson H; Ferri C; Morsica G
Virol J; 2018 Sep; 15(1):144. PubMed ID: 30227876
[TBL] [Abstract][Full Text] [Related]
2. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
6. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions.
Bagaglio S; Messina E; Hasson H; Galli A; Uberti-Foppa C; Morsica G
Viruses; 2019 Feb; 11(2):. PubMed ID: 30754682
[TBL] [Abstract][Full Text] [Related]
7. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
[TBL] [Abstract][Full Text] [Related]
8. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Peres-da-Silva A; Brandão-Mello CE; Lampe E
Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.
Bagaglio S; Andolina A; Merli M; Uberti-Foppa C; Morsica G
Viruses; 2016 Mar; 8(4):91. PubMed ID: 27023593
[TBL] [Abstract][Full Text] [Related]
12. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank.
Sharafi H; Maleki S; Alavian SM
Virus Res; 2019 Jan; 259():54-61. PubMed ID: 30401643
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection.
Rahimi P; Sharafi H; Bahramali G; SajadianFard F; Asadi NS; Alavian SM; Iranpur Mobarakeh V; Moravej SZ
Front Microbiol; 2020; 11():617375. PubMed ID: 33584581
[TBL] [Abstract][Full Text] [Related]
18. NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C.
D'Aliberti D; Cacciola I; Musolino C; Raffa G; Filomia R; Alibrandi A; Benfatto S; Beninati C; Saitta C; Giosa D; Romeo O; Raimondo G; Pollicino T
Intervirology; 2018; 61(1):1-8. PubMed ID: 30021203
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
